PMS2 and carcinoma of duodenum: The risk of duodenal carcinoma was reported to be the highest for the MLH1 pathogenic variant carriers (6.5% for MLH1 and 2% for MSH2), and no small bowel cancers were observed in patients with the constitutional MSH6 or PMS2 pathogenic variants [7].